Publications by authors named "G G Gregory"

Increasing the diversity of bio-based polymers is needed to address the combined problems of plastic pollution and greenhouse gas emissions. The magnitude of the problems necessitates rapid discovery of new materials; however, identification of appropriate chemistries maybe slow using current iterative methods. Machine learning (ML) methods could significantly expedite new material discovery and property identification.

View Article and Find Full Text PDF

The variability in vestibular schwannoma growth rates greatly complicates clinical treatment. Management options are limited to radiological observation, surgery, radiotherapy and, in specific cases, bevacizumab therapy. As such, there is a pressing requirement for growth restricting drugs for vestibular schwannoma.

View Article and Find Full Text PDF

Background: Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a second-line therapy. We investigated the efficacy and safety of glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) versus rituximab (R)-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma.

Methods: The phase 3, randomised, open-label STARGLO trial was done at 62 centres in 13 countries in Asia and Australia, Europe, and North America.

View Article and Find Full Text PDF

Process design strategies are important to prevent or reduce food safety risks in production systems. In this sense, the Codex Alimentarius presents a set of principles for good hygiene practices to guide food producers. However, studies in food safety often focus on analyzing and controlling implemented production processes without a policy of designing them with a preventive logic, leading to resource misallocation and noncompliance.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers examined treatment options for primary CNS lymphoma in adult patients, focusing on five chemotherapy regimens that include high-dose methotrexate (HD-MTX).
  • Out of 204 patients in the study, a significant majority (93%) received various combinations of HD-MTX and other drugs, with the MPV/Ara-C regimen showing the best results in progression-free and overall survival rates.
  • The study concluded that using tailored treatment strategies can boost recovery rates, especially for older patients not suited for more aggressive therapies.
View Article and Find Full Text PDF